Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_assertion type Assertion NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_head.
- NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_assertion description "[Including this patient, we administered 150 mg erlotinib daily to nine NSCLC patients with CNS metastases and measured the plasma and CSF concentrations just before administration on day 8.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_provenance.
- NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_assertion evidence source_evidence_literature NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_provenance.
- NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_assertion SIO_000772 21681573 NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_provenance.
- NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_assertion wasDerivedFrom befree-20150227 NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_provenance.
- NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_assertion wasGeneratedBy ECO_0000203 NP531210.RAcsqr4_sNA6Kx6mIE0PZVroLa6PkPzZY_ceZfEgCZs1c130_provenance.